News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
736,056 Results
Type
Article (42214)
Company Profile (269)
Press Release (693559)
Multimedia
Podcasts (94)
Webinars (21)
Section
Business (205700)
Career Advice (2051)
Deals (35658)
Drug Delivery (134)
Drug Development (81721)
Employer Resources (173)
FDA (16570)
Job Trends (15057)
News (348057)
Policy (32859)
Tag
2027 BioCapital Elite (1)
2027 BioCapital Standard (1)
2027 BioMidwest Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (3)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Genetown Standard (2)
2027 Pharm Country Elite (2)
2027 Pharm Country Standard (5)
Academia (2650)
Academic (1)
Accelerated approval (53)
ADA (42)
Adcomms (27)
Allergies (179)
Alliances (49883)
ALS (220)
Alzheimer's disease (1814)
Antibody-drug conjugate (ADC) (493)
Approvals (16992)
Artificial intelligence (701)
ASCO (327)
Autoimmune disease (322)
Automation (58)
Bankruptcy (364)
Best Places to Work (11663)
BIOSECURE Act (20)
Biosimilars (228)
Biotechnology (175)
Bladder cancer (200)
Brain cancer (73)
Breast cancer (783)
Cancer (6122)
Cardiovascular disease (499)
Career advice (1743)
Career pathing (45)
CAR-T (347)
CDC (57)
Celiac Disease (3)
Cell therapy (934)
Cervical cancer (52)
Clinical research (71326)
Collaboration (2131)
Company closure (5)
Compensation (1467)
Complete response letters (82)
COVID-19 (2764)
CRISPR (113)
C-suite (1180)
Cystic fibrosis (155)
Data (8387)
Decentralized trials (3)
Denatured (28)
Depression (166)
Dermatology (93)
Diabetes (646)
Diagnostics (7019)
Digital health (60)
Diversity (13)
Diversity, equity & inclusion (45)
Drug discovery (335)
Drug pricing (202)
Drug shortages (31)
Duchenne muscular dystrophy (292)
Earnings (92272)
Editorial (66)
Employer branding (21)
Employer resources (152)
Events (120739)
Executive appointments (1103)
FDA (20424)
Fibrodysplasia Ossificans Progressiva (8)
Friedreich's ataxia (19)
Frontotemporal dementia (35)
Funding (1788)
Gene editing (240)
Generative AI (59)
Gene therapy (734)
GLP-1 (1082)
Government (4772)
Grass and pollen (6)
Guidances (414)
Healthcare (19162)
Hematology (192)
HIV (84)
Huntington's disease (58)
IgA nephropathy (110)
Immunology and inflammation (293)
Immuno-oncology (99)
Indications (202)
Infectious disease (3122)
Inflammatory bowel disease (218)
Inflation Reduction Act (14)
Influenza (139)
Intellectual property (305)
Interviews (323)
IPO (16686)
IRA (50)
Job creations (3687)
Job search strategy (1444)
JPM (58)
Kidney cancer (20)
Labor market (108)
Layoffs (570)
Leadership (43)
Legal (7971)
Liver cancer (103)
Longevity (33)
Lung cancer (818)
Lymphoma (453)
Machine learning (61)
Management (59)
Manufacturing (1094)
MASH (205)
Medical device (13995)
Medtech (14139)
Mergers & acquisitions (20244)
Metabolic disorders (1603)
mRNA (221)
Multiple sclerosis (194)
NASH (17)
Neurodegenerative disease (441)
Neuropsychiatric disorders (107)
Neuroscience (3399)
Neurotech (1)
NextGen: Class of 2026 (6543)
Non-profit (4563)
Now hiring (79)
Obesity (738)
Opinion (291)
Ovarian cancer (233)
Pain (260)
Pancreatic cancer (329)
Parkinson's disease (382)
Partnered (33)
Patents (615)
Patient recruitment (709)
Peanut (65)
People (60061)
Pharmaceutical (58)
Pharmacy benefit managers (33)
Phase 1 (22267)
Phase 2 (31415)
Phase 3 (23368)
Pipeline (9361)
Policy (326)
Postmarket research (2574)
Preclinical (9482)
Press Release (68)
Prostate cancer (326)
Psychedelics (54)
Radiopharmaceuticals (338)
Rare diseases (1121)
Real estate (6035)
Recruiting (70)
Regulatory (25660)
Reports (56)
Research institute (2460)
Resumes & cover letters (356)
Rett syndrome (41)
RNA editing (23)
RSV (88)
Schizophrenia (180)
Series A (300)
Series B (220)
Service/supplier (11)
Sickle cell disease (117)
Special edition (24)
Spinal muscular atrophy (168)
Sponsored (48)
Startups (3669)
State (2)
Stomach cancer (18)
Supply chain (132)
Tariffs (88)
The Weekly (64)
Vaccines (1129)
Venture capital (114)
Weight loss (472)
Women's health (131)
Worklife (20)
Date
Today (140)
Last 7 days (668)
Last 30 days (3100)
Last 365 days (30419)
2026 (14667)
2025 (30233)
2024 (35268)
2023 (40137)
2022 (51248)
2021 (55806)
2020 (54208)
2019 (46690)
2018 (35176)
2017 (32278)
2016 (31679)
2015 (37798)
2014 (31493)
2013 (26566)
2012 (28759)
2011 (29445)
2010 (27554)
Location
Africa (746)
Alabama (94)
Alaska (7)
Arizona (354)
Arkansas (14)
Asia (40065)
Australia (6567)
California (13732)
Canada (3868)
China (1433)
Colorado (583)
Connecticut (600)
Delaware (424)
Europe (86747)
Florida (2080)
Georgia (439)
Hawaii (3)
Idaho (63)
Illinois (1109)
India (93)
Indiana (620)
Iowa (23)
Japan (565)
Kansas (132)
Kentucky (50)
Louisiana (59)
Maine (76)
Maryland (1636)
Massachusetts (9819)
Michigan (370)
Minnesota (739)
Mississippi (7)
Missouri (147)
Montana (33)
Nebraska (29)
Nevada (145)
New Hampshire (84)
New Jersey (3598)
New Mexico (30)
New York (3589)
North Carolina (1729)
North Dakota (9)
Northern California (6915)
Ohio (409)
Oklahoma (23)
Oregon (41)
Pennsylvania (2744)
Puerto Rico (29)
Rhode Island (51)
South America (1121)
South Carolina (86)
South Dakota (2)
Southern California (5438)
Tennessee (220)
Texas (2191)
United States (48411)
Utah (406)
Vermont (1)
Virginia (333)
Washington D.C. (81)
Washington State (1097)
West Virginia (4)
Wisconsin (129)
Wyoming (2)
736,056 Results for "oculusgen biomedical inc obi".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
OBI Pharma Announces Ten Poster Presentations at the AACR 2026 Annual Meeting for GlycOBI(R) Glycan-based Site-Specific Antibody-Drug Conjugates (ADCs): Mono and Bi-Specific (inc. Dual payload) and Obrion(TM) ADC enabling technologies
April 15, 2026
·
16 min read
Press Releases
OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC
January 12, 2026
·
5 min read
Press Releases
DeepoMe Introduces the First Biomedical World Model for Chronic Disease Management and Aging Intervention
New preprint by Jianghui Xiong, PhD, and the DeepoMe team introduces SteeraMed, a steerable biomedical world model for N-of-1 intervention reasoning across chronic diseases and aging
May 26, 2026
·
1 min read
Press Releases
OBI-902 Has Been Granted by US FDA for Orphan Drug Designation for the Treatment of Cholangiocarcinoma
November 18, 2025
·
6 min read
Press Releases
OBI Pharma Announces Phase 1/2 Study Initiation for OBI-902, a TROP2 Targeted Antibody-Drug Conjugate Therapy (ADC) in Advanced Solid Tumors
September 2, 2025
·
5 min read
OBI Pharma Announces Poster Presentations at the AACR 2024 Annual Meeting for OBI-992 and GlycOBI™ ADC platformPoster Presentations to highlight the latest research on OBI-992 (anti-TROP2 ADC) and OBI’s novel GlycOBI ADC platform
OBI Pharma, Inc. announced preclinical data for OBI-992, a potential best-in-class anti-TROP2 Antibody-Drug Conjugate.
March 18, 2024
·
6 min read
Press Releases
Impact BioMedical Inc. Reports Going Concern Audit Opinion in 2025 10-K Filing While Continuing Strategic Merger Plans
April 5, 2026
·
1 min read
Press Releases
Lifecore Biomedical Signs Agreement with New Biopharmaceutical Customer
June 2, 2026
·
5 min read
Press Releases
Lifecore Biomedical to Participate at CDMO Live Europe
May 13, 2026
·
1 min read
Press Releases
OBI Pharma Announces Poster Presentations at the AACR 2025 Annual Meeting for OBI-992 and OBI-902 Antibody-Drug Conjugates (ADCs), GlycOBI® and ThiOBI® ADC enabling technologies, the OBI-3424 prodrug, and Globo H (GH) science
April 23, 2025
·
12 min read
1 of 73,606
Next
